{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T10:01:39Z","timestamp":1787652099523,"version":"build-2736575974"},"reference-count":42,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T00:00:00Z","timestamp":1732752000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T00:00:00Z","timestamp":1732752000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Weight loss mediated by glucagon\u2010like peptide\u20101 (GLP\u20101) analogues is lower in patients with type 2 diabetes versus those without. Type 2 diabetes and obesity are risk factors for metabolic dysfunction\u2010associated steatotic liver disease (MASLD) and associated steatohepatitis (MASH). We evaluated weight changes in adults with MASLD\/MASH with or without type 2 diabetes receiving the GLP\u20101 analogue semaglutide.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>\n                      This was a post hoc analysis of data from three 48\u201372\u2010week randomised trials investigating the effect of semaglutide versus placebo in adults with MASLD (NCT03357380) or biopsy\u2010confirmed MASH (NCT02970942 and NCT03987451). Pooled data for semaglutide (0.4\u2009mg once daily and 2.4\u2009mg once weekly [\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009163]) and placebo (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009137) were analysed at 1\u2009year. Weight changes were analysed by type 2 diabetes status (type 2 diabetes [\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009209], pre\u2010type 2 diabetes [\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200951] and no diabetes [\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200940]) and by other cardiometabolic risk parameters using analysis of covariance and Spearman's rank correlations.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The overall mean weight change was \u221211.1\u2009kg (\u221211.7%) and \u22120.7\u2009kg (\u22120.6%) with semaglutide and placebo, respectively. While numerically higher for people without type 2 diabetes, estimated treatment differences with semaglutide versus placebo were similar overall for people with type 2 diabetes (\u221210.2\u2009kg; \u221210.8%), pre\u2010type 2 diabetes (\u22129.8\u2009kg; \u221210.2%) and no diabetes (\u221211.6\u2009kg; \u221213.1%). Differences between groups were not statistically significant (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&gt;\u20090.50 for all). Baseline fasting plasma glucose, glycated haemoglobin, insulin levels, insulin resistance and lipids did not correlate with weight change.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>People with MASLD\/MASH had similar semaglutide\u2010mediated weight loss regardless of type 2 diabetes status and other cardiometabolic risk parameters.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.16065","type":"journal-article","created":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T23:40:08Z","timestamp":1732837208000},"page":"710-718","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Similar weight loss with semaglutide regardless of diabetes and cardiometabolic risk parameters in individuals with metabolic dysfunction\u2010associated steatotic liver disease: Post hoc analysis of three randomised controlled trials"],"prefix":"10.1111","volume":"27","author":[{"given":"Matthew J.","family":"Armstrong","sequence":"first","affiliation":[{"name":"Liver Unit Queen Elizabeth University Hospital  Birmingham UK"},{"name":"National Institute for Health Research Birmingham Biomedical Research Centre at University Hospitals Birmingham NHS Foundation Trust  Birmingham UK"},{"name":"Centre for Liver &amp; Gastrointestinal Research, Institute of Immunology and Immunotherapy University of Birmingham  Birmingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Okanoue","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology Saiseikai Suita Hospital  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mads","family":"Sundby Palle","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S  S\u00f8borg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne\u2010Sophie","family":"Sejling","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S  S\u00f8borg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Tawfik","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S  S\u00f8borg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Roden","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Diabetology, Medical Faculty and University Hospital D\u00fcsseldorf Heinrich\u2010Heine University D\u00fcsseldorf  D\u00fcsseldorf Germany"},{"name":"Institute for Clinical Diabetology, German Diabetes Center Leibniz Center for Diabetes Research  D\u00fcsseldorf Germany"},{"name":"German Center for Diabetes Research Partner D\u00fcsseldorf  M\u00fcnchen\u2010Neuherberg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,11,28]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.06.003"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.7570\/jomes23052"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.04.036"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000323"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2022.03.010"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.04.031"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.11.004"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.04.005"},{"key":"e_1_2_11_10_1","unstructured":"FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease [press release].2024."},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-022-05787-2"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc23-S004"},{"key":"e_1_2_11_13_1","unstructured":"FDA.OZEMPIC prescribing information.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209637lbl.pdf. Accessed 22 January 2024"},{"key":"e_1_2_11_14_1","unstructured":"FDA.WEGOVY prescribing information.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/215256s000lbl.pdf. Accessed 22 January 2024"},{"key":"e_1_2_11_15_1","unstructured":"ClinicalTrials.gov.Research study on whether semaglutide works in people with non\u2010alcoholic steatohepatitis (NASH) (ESSENCE).2024https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04822181. Accessed 27 March 2024"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00803-X"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028395"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16608"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(23)00068-7"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2019.07.002"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-1997"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2024.111846"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-022-02153-x"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14863"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.28.6.1526"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00213-0"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.9676"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411892"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032183"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01200-X"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.133429"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12932"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14280"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2023.01.002"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.04.015"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101122"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-0150"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30187-1"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-023-01792-w"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2023.11.018"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11901-017-0378-2"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.14734"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.16065","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/full-xml\/10.1111\/dom.16065","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.16065","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T23:53:27Z","timestamp":1775865207000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.16065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,28]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1111\/dom.16065"],"URL":"https:\/\/doi.org\/10.1111\/dom.16065","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/DOM.16065\/v1\/review5","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.16065\/v1\/review4","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.16065\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.16065\/v1\/review3","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.16065\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.16065\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.16065\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.16065\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.16065\/v2\/response1","asserted-by":"object"}]},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,28]]},"assertion":[{"value":"2024-08-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}